

REFERENCES

- [0363] 1. Hamad, B., *The antibiotics market*. *Nat Rev Drug Discov*, 2010. 9(9): p. 675-676.
- [0364] 2. Van Boeckel, T. P., et al., *Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data*. *The Lancet Infectious Diseases*, 2014. 14(8): p. 742-750.
- [0365] 3. Versporten, A., et al., *Antibiotic use in eastern Europe: a cross-national database study in coordination with the WHO Regional Office for Europe*. *Lancet Infectious Diseases*, 2014. 14(5): p. 381-387.
- [0366] 4. Strynadka, N. C. J., et al., *Molecular structure of the acyl-enzyme intermediate in [beta]-lactam hydrolysis at 1.7 Å resolution*. *Nature*, 1992. 359(6397): p. 700-705.
- [0367] 5. Drawz, S. M. and R. A. Bonomo, *Three Decades of β-Lactamase Inhibitors*. *Clinical Microbiology Reviews*, 2010. 23(1): p. 160-201.
- [0368] 6. Ambler, R. P., *The Structure of </i></math>β-Lactamases*. *Philosophical Transactions of the Royal Society of London. B, Biological Sciences*, 1980. 289(1036): p. 321.
- [0369] 7. Bush, K., *The ABCD's of β-lactamase nomenclature*. *Journal of Infection and Chemotherapy*, 2013. 19(4): p. 549-559.
- [0370] 8. King, A. M., et al., *Structural and Kinetic Characterization of Diazabicyclooctanes as Dual Inhibitors of Both Serine-β-Lactamases and Penicillin-Binding Proteins*. *ACS Chemical Biology*, 2016. 11(4): p. 864-868.
- [0371] 9. Brem, J., et al., *Structural basis of metallo-β-lactamase, serine-β-lactamase and penicillin-binding protein inhibition by cyclic boronates*. *Nature Communications*, 2016. 7.
- [0372] 10. Drawz, S. M., K. M. Papp-Wallace, and R. A. Bonomo, *New beta-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World*. *Antimicrobial Agents and Chemotherapy*, 2014. 58(4): p. 1835-1846.
- [0373] 11. Al Roomi, L. G., et al., *Amoxycillin and clavulanic acid in the treatment of urinary infection*. *Archives of Disease in Childhood*, 1984. 59(3): p. 256-259.
- [0374] 12. Reading, C. and M. Cole, *Clavulanic Acid: a Beta-Lactamase-Inhibiting Beta-Lactam from Streptomyces claviger*. *Antimicrobial Agents and Chemotherapy*, 1977. 11(5): p. 852-857.
- [0375] 13. Fass, R. J. and R. B. Prior, *Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate*. *Antimicrobial Agents and Chemotherapy*, 1989. 33(8): p. 1268-1274.
- [0376] 14. Finlay, J., L. Miller, and J. A. Poupart, *A review of the antimicrobial activity of clavulanate*. *Journal of Antimicrobial Chemotherapy*, 2003. 52(1): p. 18-23.
- [0377] 15. Sulton, D., et al., *Clavulanic acid inactivation of SHV-1 and the inhibitor-resistant 5130G SHV-1 beta-lactamase—Insights into the mechanism of inhibition*. *Journal of Biological Chemistry*, 2005. 280(42): p. 35528-35536.
- [0378] 16. Stachyra, T., et al., *Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor*. *Antimicrob Agents Chemother*, 2010. 54(12): p. 5132-8.
- [0379] 17. Coleman, K., *Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors*. *Current Opinion in Microbiology*, 2011. 14(5): p. 550-555.
- [0380] 18. Wang, D. Y., et al., *The road to avibactam: the first clinically useful non-beta-lactam working somewhat like a beta-lactam*. *Future Medicinal Chemistry*, 2016. 8(10): p. 1063-1084.
- [0381] 19. Abboud, M. I., et al., *Interaction of Avibactam with Class B Metallo-beta-Lactamases*. *Antimicrobial Agents and Chemotherapy*, 2016. 60(10): p. 5655-5662.
- [0382] 20. Hecker, S. J., et al., *Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases*. *Journal of Medicinal Chemistry*, 2015. 58(9): p. 3682-3692.
- [0383] 21. Cahill, S. T., et al., *Cyclic Boronates Inhibit All Classes of beta-Lactamase*. *Antimicrob Agents Chemother*, 2017.
- [0384] 22. Ryan, R. P., et al., *The versatility and adaptation of bacteria from the genus Stenotrophomonas*. *Nat Rev Micro*, 2009. 7(7): p. 514-525.
- [0385] 23. Brooke, J. S., *Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen*. *Clinical Microbiology Reviews*, 2012. 25(1): p. 2-41.
- [0386] 24. de Vrankrijker, A. M. M., T. F. W. Wolfs, and C. K. van der Ent, *Challenging and emerging pathogens in cystic fibrosis*. *Paediatric Respiratory Reviews*, 2010. 11(4): p. 246-254.
- [0387] 25. Alonso, A. and J. L. Martinez, *Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia*. *Antimicrob Agents Chemother*, 2000. 44(11): p. 3079-86.
- [0388] 26. Gould, V. C. and M. B. Avison, *SmeDEF-mediated antimicrobial drug resistance in Stenotrophomonas maltophilia clinical isolates having defined phylogenetic relationships*. *J Antimicrob Chemother*, 2006. 57(6): p. 1070-6.
- [0389] 27. Garcia-Leon, G., et al., *High-level quinolone resistance is associated with the overexpression of smeVWX in Stenotrophomonas maltophilia clinical isolates*. *Clinical Microbiology and Infection*, 2015. 21(5): p. 464-467.
- [0390] 28. Gould, V. C., A. Okazaki, and M. B. Avison, *Coordinate hyperproduction of SmeZ and SmeJK efflux pumps extends drug resistance in Stenotrophomonas maltophilia*. *Antimicrob Agents Chemother*, 2013. 57(1): p. 655-7.
- [0391] 29. Walsh, T. R., et al., *Sequence-Analysis of the L1 Metallo-Beta-Lactamase from Xanthomonas-Maltophilia*. *Biochimica Et Biophysica Acta-Gene Structure and Expression*, 1994. 1218(2): p. 199-201.
- [0392] 30. Walsh, T. R., A. P. MacGowan, and P. M. Bennett, *Sequence analysis and enzyme kinetics of the L2 serine beta-lactamase from Stenotrophomonas maltophilia*. *Antimicrobial Agents and Chemotherapy*, 1997. 41(7): p. 1460-1464.
- [0393] 31. Gould, V. C., A. Okazaki, and M. B. Avison, *Beta-lactam resistance and beta-lactamase expression in clinical Stenotrophomonas maltophilia isolates having defined phylogenetic relationships*. *J Antimicrob Chemother*, 2006. 57(2): p. 199-203.
- [0394] 32. Lemmen, S. W., et al., *Comparison of serum bactericidal activity of ceftazidime, ciprofloxacin and meropenem against Stenotrophomonas maltophilia*. *Journal of Antimicrobial Chemotherapy*, 2001. 47(1): p. 118-120.
- [0395] 33. Okazaki, A. and M. B. Avison, *Induction of L1 and L2 beta-lactamase production in Stenotrophomonas*